New drug aims to shield cancer patients from chemo side effects
Disease control
Not yet recruiting
This trial tests if trilaciclib can protect the bone marrow in people with limited-stage small cell lung cancer who are getting chemotherapy. About 120 participants will receive either trilaciclib or a placebo. The goal is to see if the drug reduces severe low white blood cell co…
Phase: PHASE3 • Sponsor: Pharmacosmos A/S • Aim: Disease control
Last updated May 17, 2026 03:13 UTC